AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 228 filers reported holding AXSOME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.64 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $217 | +112.7% | 3,112 | +120.4% | 0.00% | – |
| Q2 2023 | $102 | +7.4% | 1,412 | -8.4% | 0.00% | – |
| Q1 2023 | $95 | -20.2% | 1,541 | 0.0% | 0.00% | – |
| Q4 2022 | $119 | -99.8% | 1,541 | 0.0% | 0.00% | – |
| Q3 2022 | $69,000 | +16.9% | 1,541 | 0.0% | 0.00% | – |
| Q2 2022 | $59,000 | -13.2% | 1,541 | 0.0% | 0.00% | – |
| Q1 2022 | $68,000 | +17.2% | 1,541 | 0.0% | 0.00% | – |
| Q4 2021 | $58,000 | +13.7% | 1,541 | 0.0% | 0.00% | – |
| Q3 2021 | $51,000 | -51.0% | 1,541 | 0.0% | 0.00% | – |
| Q2 2021 | $104,000 | -9.6% | 1,541 | -25.0% | 0.00% | – |
| Q1 2021 | $115,000 | -31.1% | 2,055 | 0.0% | 0.00% | – |
| Q4 2020 | $167,000 | +14.4% | 2,055 | 0.0% | 0.00% | – |
| Q3 2020 | $146,000 | -13.1% | 2,055 | 0.0% | 0.00% | – |
| Q2 2020 | $168,000 | +75.0% | 2,055 | +27.6% | 0.00% | – |
| Q1 2020 | $96,000 | -41.8% | 1,610 | 0.0% | 0.00% | – |
| Q4 2019 | $165,000 | +111.5% | 1,610 | -47.0% | 0.00% | – |
| Q2 2019 | $78,000 | – | 3,035 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,132,645 | $37,332,000 | 32.86% |
| MORGAN JESS S & CO INC | 113,430 | $3,739,000 | 2.47% |
| Fairmount Funds Management LLC | 187,598 | $6,183,000 | 2.25% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 1,423,653 | $46,924,000 | 1.43% |
| WMS Partners, LLC | 250,000 | $8,240,000 | 1.21% |
| Beck Bode, LLC | 102,127 | $3,366,000 | 0.94% |
| RTW INVESTMENTS, LP | 1,616,497 | $53,280,000 | 0.80% |
| MPM BioImpact LLC | 110,155 | $3,631,000 | 0.56% |
| Endurant Capital Management LP | 52,048 | $1,716,000 | 0.39% |
| Bellevue Group AG | 752,945 | $24,817,000 | 0.25% |